1 Powerhouse Drug in Celgene's Pipeline (CELG)

1 Powerhouse Drug in Celgene's Pipeline

To kick things off at this week's BIO CEO conference, conducted by the Biotech Industry Organization, Celgene's (NASDAQ: CELG ) CEO Bob Hugin gave a fireside chat. In this video, Motley Fool health care bureau chief Brenton Flynn highlights one of the topics discussed -- the company's new inflammation drug Apremilast -- and one of the biggest reasons why this could be a winner over the existing crop of TNF inhibitors.

Is Celgene still a buy?
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. While Celgene might be a safer stock than its small biotech brethren, investors need to know about the key opportunities and risks facing the company. We run through them all in The Motley Fool's brand new premium report on Celgene. To claim your copy today, simply click here now.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.